Journal of International Oncology››2020,Vol. 47››Issue (10): 598-605.doi:10.3760/cma.j.cn371439-20200113-00085
• Original Articles •Previous ArticlesNext Articles
Han Jing1, Yuan Shuai2, Pu Yan1, Liu Huibin1()
Received:
2020-01-13Revised:
2020-04-15Online:
2020-10-08Published:
2020-11-20Contact:
Liu Huibin E-mail:1047893820@qq.comSupported by:
Han Jing, Yuan Shuai, Pu Yan, Liu Huibin. Analysis of SKA1 gene expression in clear cell renal cell carcinoma and its clinical significance based on bioinformatics database[J]. Journal of International Oncology, 2020, 47(10): 598-605.
"
临床病理特征 | 例数 | SKA1基因表达 | χ2值 | P值 | |
---|---|---|---|---|---|
高表达 (n=216) |
低表达 (n=216) |
||||
性别 | |||||
男 | 286 | 152(70.4) | 134(62.0) | 3.352 | 0.067 |
女 | 146 | 64(29.6) | 82(38.0) | ||
年龄(岁) | |||||
<59 | 205 | 108(50.0) | 97(44.9) | 1.123 | 0.289 |
≥59 | 227 | 108(50.0) | 119(55.1) | ||
Fuhrman分级 | |||||
G1+G2 | 211 | 107(49.5) | 104(48.1) | ||
G3+G4 | 217 | 109(50.5) | 108(50.0) | 3.758 | 0.184 |
Gx | 4 | 0(0.0) | 4(1.9) | ||
AJCC分期 | |||||
Ⅰ~Ⅱ | 278 | 116(53.7) | 162(75.0) | 21.352 | <0.001 |
Ⅲ~Ⅳ | 154 | 100(46.3) | 54(25.0) | ||
T分期 | |||||
T1 | 231 | 96(44.4) | 135(62.5) | ||
T2 | 60 | 28(13.0) | 32(14.8) | 19.967 | <0.001 |
T3 | 138 | 90(41.7) | 48(22.2) | ||
T4 | 3 | 2(0.9) | 1(0.5) | ||
N分期 | |||||
N0 | 193 | 107(49.5) | 86(39.8) | ||
N1 | 12 | 10(4.6) | 2(1.0) | 11.323 | 0.003 |
Nx | 227 | 99(45.9) | 128(59.2) | ||
M分期 | |||||
M0 | 353 | 174(80.6) | 179(82.9) | ||
M1 | 53 | 39(18.1) | 14(6.5) | 27.248 | <0.001 |
Mx | 26 | 3(1.3) | 23(10.6) |
"
临床病理特征 | 例数 | SKA1相对表达量 | t值 | P值 |
---|---|---|---|---|
性别 | ||||
男 | 62 | 0.309±0.145 | 0.129 | 0.898 |
女 | 14 | 0.266±0.154 | ||
年龄(岁) | ||||
>60 | 26 | 0.306±0.145 | 0.311 | 0.757 |
≤60 | 50 | 0.296±0.150 | ||
肿瘤直径(cm) | ||||
≥5.9 | 23 | 0.310±0.148 | 0.598 | 0.552 |
<5.9 | 53 | 0.293±0.147 | ||
AJCC分期 | ||||
Ⅰ~Ⅱ | 52 | 0.276±0.151 | 2.445 | 0.017 |
Ⅲ~Ⅳ | 24 | 0.354±0.124 | ||
Fuhrman分级 | ||||
G1+G2 | 50 | 0.288±0.137 | 1.159 | 0.250 |
G3+G4 | 26 | 0.329±0.164 | ||
淋巴结转移 | ||||
有 | 11 | 0.286±0.141 | 2.242 | 0.028 |
无 | 65 | 0.391±0.151 | ||
远端转移 | ||||
有 | 70 | 0.295±0.153 | 0.988 | 0.326 |
无 | 6 | 0.358±0.060 |
"
数据库 | ID | 注释 | P值 |
---|---|---|---|
Gene Ontology | GO:0000779 | 浓缩染色体,着丝粒区域 | <0.001 |
GO:0031110 | 微管聚合或解聚的调控 | 0.001 | |
GO:0099080 | 多分子复合物 | 0.003 | |
GO:0005856 | 细胞骨架 | 0.006 | |
GO:0031109 | 微管聚合或解聚 | 0.006 | |
GO:0032886 | 微管生物学过程的调控 | 0.007 | |
GO:0043228 | 非质膜结合细胞器 | 0.011 | |
GO:0070507 | 微管细胞骨架组织的调控 | 0.011 | |
GO:0033043 | 细胞器组织的调控 | 0.019 | |
GO:0007010 | 细胞骨架组织 | 0.024 | |
GO:0022402 | 细胞周期过程 | 0.035 | |
Reactome | R-HSA-141444 | 通过MAD2抑制因子增强非着丝粒信号通路 | 0.002 |
R-HSA-141424 | 着丝粒信号增强 | 0.002 | |
R-HSA-69618 | 有丝分裂纺锤体检查点 | 0.002 | |
R-HSA-2500257 | 姐妹染色单体凝聚力的分解 | 0.002 | |
R-HSA-5663220 | 激活肌动蛋白 | 0.002 | |
R-HSA-2467813 | 姐妹染色单体的分离 | 0.003 | |
R-HSA-68882 | 有丝分裂后期 | 0.003 | |
R-HSA-2555396 | 有丝分裂中期和后期 | 0.003 | |
R-HSA-68877 | 有丝分裂前中期 | 0.003 | |
R-HSA-69620 | 细胞周期检查点 | 0.005 | |
R-HSA-195258 | 效应器 | 0.006 | |
R-HSA-68886 | M相 | 0.007 | |
R-HSA-194315 | Rho GTPase 介导的信号通路 | 0.008 | |
R-HSA-69278 | 细胞周期,有丝分裂 | 0.009 | |
R-HSA-1640170 | 细胞周期 | 0.011 |
[1] | Capitanio U, Montorsi F. Renal cancer[J]. Lancet, 2016,387(10021):894-906. DOI: 10.1016/S0140-6736(15)00046-X. pmid:26318520 |
[2] | Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012[J]. Int J Cancer, 2015,136(5):E359-E386. DOI: 10.1002/ijc.29210. pmid:25220842 |
[3] | Rini BI, Campbell SC, Escudier B. Renal cell carcinoma[J]. Lancet, 2009,373(9669):1119-1132. DOI: 10.1016/S0140-6736(09)60229-4. doi:10.1016/S0140-6736(09)60229-4pmid:19269025 |
[4] | Ljungberg B, Bensalah K, Canfield S, et al. EAU guidelines on renal cell carcinoma: 2014 update[J]. Eur Urol, 2015,67(5):913-924. DOI: 10.1016/j.eururo.2015.01.005. doi:10.1016/j.eururo.2015.01.005pmid:25616710 |
[5] | Joglekar AP, DeLuca JG. Chromosome segregation: Ndc80 can carry the load[J]. Curr Biol, 2009,19(10):R404-R407. DOI: 10.1016/j.cub.2009.04.014. doi:10.1016/j.cub.2009.04.014pmid:19467206 |
[6] | Zhang B, Li KY, Chen HY, et al. Spindle and kinetochore associated complex subunit 1 regulates the proliferation of oral adenosquamous carcinoma CAL-27 cells in vitro[J]. Cancer Cell Int, 2013,13(1):83. DOI: 10.1186/1475-2867-13-83. doi:10.1186/1475-2867-13-83pmid:23962337 |
[7] | Qin X, Yuan B, Xu X, et al. Effects of short interfering RNA-mediated gene silencing of SKA1 on proliferation of hepatocellular carcinoma cells[J]. Scand J Gastroenterol, 2013,48(11):1324-1332. DOI: 10.3109/00365521.2013.828774. doi:10.3109/00365521.2013.828774pmid:24010405 |
[8] | Sun W, Yao L, Jiang B, et al. Spindle and kinetochore-associated protein 1 is overexpressed in gastric cancer and modulates cell growth[J]. Mol Cell Biochem, 2014,391(1-2):167-174. DOI: 10.1007/s11010-014-1999-1. |
[9] | Shi X, Chen X, Peng H, et al. Lentivirus-mediated silencing of spindle and kinetochore-associated protein 1 inhibits the proliferation and invasion of neuronal glioblastoma cells[J]. Mol Med Rep, 2015,11(5):3533-3538. DOI: 10.3892/mmr.2015.3175. doi:10.3892/mmr.2015.3175pmid:25573192 |
[10] | Thul PJ, Lindskog C. The human protein atlas: a spatial map of the human proteome[J]. Protein Sci, 2018,27(1):233-244. DOI: 10.1002/pro.3307. doi:10.1002/pro.3307pmid:28940711 |
[11] | Hanisch A, Silljé HH, Nigg EA. Timely anaphase onset requires a novel spindle and kinetochore complex comprising Ska1 and Ska2[J]. EMBO J, 2006,25(23):5504-5515. DOI: 10.1038/sj.emboj.7601426. |
[12] | Dong C, Wang XL, Ma BL. Expression of spindle and kinetochore-associated protein 1 is associated with poor prognosis in papillary thyroid carcinoma[J]. Dis Markers, 2015,2015:616541. DOI: 10.1155/2015/616541. doi:10.1155/2015/616541pmid:26063960 |
[13] | Ma Q, Zhang Y, Liu T, et al. Hypoxia promotes chemotherapy resistance by down-regulating SKA1 gene expression in human osteosarcoma[J]. Cancer Biol Ther, 2017,18(3):177-185. DOI: 10.1080/15384047.2017.1294285. doi:10.1080/15384047.2017.1294285pmid:28278080 |
[14] | Arai T, Okato A, Kojima S, et al. Regulation of spindle and kinetochore-associated protein 1 by antitumor miR-10a-5p in renal cell carcinoma[J]. Cancer Sci, 2017,108(10):2088-2101. DOI: 10.1111/cas.13331. doi:10.1111/cas.13331pmid:28746769 |
[15] | Yamada Y, Arai T, Kojima S, et al. Anti-tumor roles of both strands of the miR-455 duplex: their targets SKA1 and SKA3 are involved in the pathogenesis of renal cell carcinoma[J]. Oncotarget, 2018,9(42):26638-26658. DOI: 10.18632/oncotarget.25410. doi:10.18632/oncotarget.25410pmid:29928475 |
[1] | Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei.Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma: a real-world clinical study[J]. Journal of International Oncology, 2024, 51(6): 326-331. |
[2] | Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun.Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer[J]. Journal of International Oncology, 2024, 51(6): 332-337. |
[3] | Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua.Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy[J]. Journal of International Oncology, 2024, 51(5): 257-266. |
[4] | Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin.Study on the clinical relationship between inflammatory burden index and gastric cancer[J]. Journal of International Oncology, 2024, 51(5): 274-279. |
[5] | Liu Pingping, He Xuefang, Zhang Yi, Yang Xu, Zhang Shanshan, Ji Yifei.Risk factors of postoperative recurrence in patients with primary brain glioma and prediction model construction[J]. Journal of International Oncology, 2024, 51(4): 193-197. |
[6] | Wan Fang, Yang Gang, Li Rui, Wan Qijing.Expression levels and clinical significance of serum miR-497 and miR-383 in patients with esophageal cancer[J]. Journal of International Oncology, 2024, 51(4): 204-209. |
[7] | Yao Yixin, Shen Yulin.Predictive value of serum SOCS3 and TXNIP levels for the prognosis of patients with hepatocellular carcinoma treated with TACE[J]. Journal of International Oncology, 2024, 51(4): 217-222. |
[8] | Sun Weiwei, Yao Xuemin, Wang Pengjian, Wang Jing, Jia Jinghao.Exploration of prognostic factors and nomogram construction for advanced non-small cell lung cancer treated with immunotherapy based on hematologic indexes[J]. Journal of International Oncology, 2024, 51(3): 143-150. |
[9] | Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan.Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer[J]. Journal of International Oncology, 2024, 51(3): 175-180. |
[10] | Peng Qin, Cai Yuting, Wang Wei.Advances on KPNA2 in liver cancer[J]. Journal of International Oncology, 2024, 51(3): 181-185. |
[11] | Chen Boguang, Wang Sugui, Zhang Yongjie.Role of serum cholinesterase and inflammatory markers in the prognosis of stage ⅠA -ⅢA breast cancer[J]. Journal of International Oncology, 2024, 51(2): 73-82. |
[12] | Jin Xudong, Chen Zhongjian, Mao Weimin.Research progress on the role of MTAP in malignant mesothelioma[J]. Journal of International Oncology, 2024, 51(2): 99-104. |
[13] | Huang Zhen, Chen Yongshun.Research progress of circulating tumor DNA in the diagnosis and treatment of hepatocellular carcinoma[J]. Journal of International Oncology, 2024, 51(1): 59-64. |
[14] | Wang Xiao, Li Ying, Luo Yujie, Jin Shu.Study on the prognostic value of serological indicators for nasopharyngeal carcinoma based on nomogram model[J]. Journal of International Oncology, 2023, 50(8): 463-469. |
[15] | Liu Debao, Sun Ziwen, Lu Shoutang, Xu Haidong.Expression and clinical significance of ASB6 in colorectal cancer tissues[J]. Journal of International Oncology, 2023, 50(8): 470-474. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||